211 related articles for article (PubMed ID: 29070416)
1. Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs.
Holzer P
Chimia (Aarau); 2017 Oct; 71(10):716-721. PubMed ID: 29070416
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Holzer P; Masuya K; Furet P; Kallen J; Valat-Stachyra T; Ferretti S; Berghausen J; Bouisset-Leonard M; Buschmann N; Pissot-Soldermann C; Rynn C; Ruetz S; Stutz S; Chène P; Jeay S; Gessier F
J Med Chem; 2015 Aug; 58(16):6348-58. PubMed ID: 26181851
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
Furet P; Masuya K; Kallen J; Stachyra-Valat T; Ruetz S; Guagnano V; Holzer P; Mah R; Stutz S; Vaupel A; Chène P; Jeay S; Schlapbach A
Bioorg Med Chem Lett; 2016 Oct; 26(19):4837-4841. PubMed ID: 27542305
[TBL] [Abstract][Full Text] [Related]
4. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
5. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
[TBL] [Abstract][Full Text] [Related]
6. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
7. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
Gonzalez AZ; Eksterowicz J; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Duquette J; Fox BM; Fu J; Huang X; Houze JB; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; McMinn DL; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Medina JC; Sun D
J Med Chem; 2014 Mar; 57(6):2472-88. PubMed ID: 24548297
[TBL] [Abstract][Full Text] [Related]
8. Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Jeay S; Ferretti S; Holzer P; Fuchs J; Chapeau EA; Wartmann M; Sterker D; Romanet V; Murakami M; Kerr G; Durand EY; Gaulis S; Cortes-Cros M; Ruetz S; Stachyra TM; Kallen J; Furet P; Würthner J; Guerreiro N; Halilovic E; Jullion A; Kauffmann A; Kuriakose E; Wiesmann M; Jensen MR; Hofmann F; Sellers WR
Cancer Res; 2018 Nov; 78(21):6257-6267. PubMed ID: 30135191
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Vaupel A; Holzer P; Ferretti S; Guagnano V; Kallen J; Mah R; Masuya K; Ruetz S; Rynn C; Schlapbach A; Stachyra T; Stutz S; Todorov M; Jeay S; Furet P
Bioorg Med Chem Lett; 2018 Nov; 28(20):3404-3408. PubMed ID: 30217415
[TBL] [Abstract][Full Text] [Related]
10. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
11. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
[TBL] [Abstract][Full Text] [Related]
12. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
13. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Sun D; Li Z; Rew Y; Gribble M; Bartberger MD; Beck HP; Canon J; Chen A; Chen X; Chow D; Deignan J; Duquette J; Eksterowicz J; Fisher B; Fox BM; Fu J; Gonzalez AZ; Gonzalez-Lopez De Turiso F; Houze JB; Huang X; Jiang M; Jin L; Kayser F; Liu JJ; Lo MC; Long AM; Lucas B; McGee LR; McIntosh J; Mihalic J; Oliner JD; Osgood T; Peterson ML; Roveto P; Saiki AY; Shaffer P; Toteva M; Wang Y; Wang YC; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Yu M; Zhao X; Zhou J; Zhu J; Olson SH; Medina JC
J Med Chem; 2014 Feb; 57(4):1454-72. PubMed ID: 24456472
[TBL] [Abstract][Full Text] [Related]
14. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
Wang Y; Zhu J; Liu JJ; Chen X; Mihalic J; Deignan J; Yu M; Sun D; Kayser F; McGee LR; Lo MC; Chen A; Zhou J; Ye Q; Huang X; Long AM; Yakowec P; Oliner JD; Olson SH; Medina JC
Bioorg Med Chem Lett; 2014 Aug; 24(16):3782-5. PubMed ID: 25042256
[TBL] [Abstract][Full Text] [Related]
15. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
16. p53-Mdm2 inhibitors: patent review (2009 - 2010).
Kamal A; Mohammed AA; Shaik TB
Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
[TBL] [Abstract][Full Text] [Related]
18. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitors of the p53-MDM2.
Hu CQ; Hu YZ
Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
[TBL] [Abstract][Full Text] [Related]
20. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]